Hufig: Erbrechen, Hypoglykmie bei Kombinationstherapie mit Insulin oder Sulfonylharnstoffen, gastrointestinale Beschwerden
10.1056/NEJMoa1504720 135
Species: Mouse
The dropout rate, which the cultural narrative tends to elide, is significant, somewhere between 10% and 25% of patients discontinue within the first year, the majority due to gastrointestinal side effects that for some are tolerable nuisance and for others are quality-of-life-destroying
Our cutting-edge therapies, including peptide therapy, stem cell therapy, and PRP (Platelet-Rich Plasma) therapy, are designed to treat rheumatoid arthritis and enhance joint health
In addition, it works well in formulations focused on maintaining healthy-looking skin